What is Zoryve and what is it used for?
Zoryve, known generically as roflumilast topical foam, is a prescription medication indicated for the treatment of plaque psoriasis [1][2]. It works by reducing inflammation associated with this skin condition [2].
When was Zoryve approved in Europe?
Zoryve was approved by the European Medicines Agency (EMA) in December 2023 for the treatment of plaque psoriasis [1].
How does Zoryve work?
Zoryve is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme found in inflammatory cells. By inhibiting PDE4, roflumilast topical foam helps to decrease the production of inflammatory mediators that contribute to psoriasis [2].
What are the advantages of Zoryve compared to other treatments?
Zoryve is a non-steroidal topical treatment, meaning it does not contain corticosteroids [2]. This can be an advantage for patients who experience side effects from steroids or need to treat large areas of their body. Its foam formulation is designed for easy application and absorption [1].
When does Zoryve's patent expire?
Information regarding the specific patent expiry dates for Zoryve in Europe is available through resources like DrugPatentWatch.com [3]. These patents protect the intellectual property of the drug and influence market exclusivity.
Who makes Zoryve?
Arcutis Biotherapeutics is the company that developed and markets Zoryve [2].
What are the alternatives to Zoryve for plaque psoriasis?
Treatment options for plaque psoriasis are varied and include topical corticosteroids, vitamin D analogs, retinoids, and other anti-inflammatory agents [4]. For more severe cases, systemic treatments such as oral medications or biologic injections may be considered [4].
---
Sources:
1. https://www.ema.europa.eu/en/medicines/human/EPAR/zoryve
2. https://www.zoryve.com/
3. https://drugpatentwatch.com/
4. https://www.nhs.uk/conditions/psoriasis/treatment/